Skip to content

Biologie aujourd'hui

ISSN 2105-0686

6 papers in the library · 10 citations · publishing 2019-2025

Papers

Sort Most recent Most cited

[Mechanisms of action and therapeutic perspectives of LSD: Current status].

Biologie aujourd'hui 2025 Amel Bouloufa, Sarah Delcourte, Nasser Haddjeri

Major depressive disorder (MDD) is a prevalent and disabling condition affecting over 350 million individuals worldwide. Although conventional antidepressants targeting serotonin, dopamine, and noradrenaline pathways provide benefit for many, a substantial proportion of patients experience inadequate response. Treatment-resistant depression (TRD), defined by failure to respond to at least two...

[Interest and mechanisms of action of ketamine in alcohol addiction- A review of clinical and preclinical studies].

Biologie aujourd'hui 2023 Fahd Hilal, Jérôme Jeanblanc, Mickaël Naassïla 3 citations

Alcohol Use Disorder (AUD) is a psychiatric condition characterized by chronic and excessive drinking despite negative consequences on overall health and social or occupational functioning. There are currently limited treatment options available for AUD, and the effects size and the response rates to these treatments are often low to moderate. The World Health Organization has identified the...

[Ketamine in antidepressant treatment: a revolution?].

Biologie aujourd'hui 2023 Philippe Fossati

Thirty percent of depressed patients are treatment resistant (TRD) suggesting the need of new therapeutic strategy. Recently, it has been shown that ketamine, an anesthetic agent with dissociative effects, has potent and rapid antidepressant properties. Ketamine is a ionotropic glutamatergic NMDA antagonist that inhibits gabaergic neurons. Its antidepressant effect peaks at 24 h post-treatment....

DOI: 10.1051/jbio/2023023 (opens in new tab) Full text (opens in new tab) Ketamine Algorithme de traitement Dissociation Dépression résistante +5

[Ketamine: a neuropsychotropic drug with an innovative mechanism of action].

Biologie aujourd'hui 2023 Jean-Philippe Guilloux, Thi Mai Loan Nguyen, Alain M. Gardier

Ketamine, a non-competitive antagonist of the N-methyl-D-aspartate-glutamate receptor (R-NMDA), has a rapid (from 24 h post-dose) and prolonged (up to one week) antidepressant effect in treatment resistant depression and in rodent models of anxiety/depression. Arguments regarding its cellular and molecular mechanisms underlying its antidepressant activity mainly come from animal studies....

[How can ketamine be used to manage suicidal risk?].

Biologie aujourd'hui 2023 Emilie Olié, Aiste Lengvenyte, Philippe Courtet

In France, suicidal behaviors remain a major public health issue. Depressed patients with suicidal ideation have more severe depressive symptoms, a more unfavorable disease course, and a greater number of suicide attempts than patients without suicidal ideation. Unfortunately, conventional antidepressants tend to be less effective in patients with suicidal tendencies than in those without....

DOI: 10.1051/jbio/2023029 (opens in new tab) Full text (opens in new tab) Ketamine Conduites suicidaires Kétamine Suicidal behavior +1

[Neurotrophic mechanisms of psychedelic therapy].

Biologie aujourd'hui 2019 Rémi Corne, Raymond Mongeau 7 citations

Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules....